John McKearn
QuietNamed in filings at RivervestOn the current fund
- Board seats filed
- 9
- Named on a board
- 0
all filings on record
Named in filings at RivervestOn the current fund
all filings on record
last 24 months
from a verified or cited source
| Bonum Therapeutics | Biotech & pharma | December 2021 | Vivo Innovation |
| Wugen | Not yet classified | April 2020 | None on file |
| Good Therapeutics | Not yet classified | November 2018 | None on file |
| OncoResponse | Biotech & pharma | August 2018 | ARCH Venture Partners, Greatpoint Ventures Innovation |
| Adarza BioSystems | Not yet classified | January 2017 | None on file |
| Tioma Therapeutics | Not yet classified | December 2014 | None on file |
| ZS Pharma | Not yet classified | February 2014 | None on file |
| Allakos | Biotech & pharma | December 2012 | NEA |
| Lumena Pharmaceuticals | Biotech & pharma | February 2011 | NEA |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name John McKearn on the board, based on 4 filed seats with a verified or cited source.
5 more filed seats not yet classified, left out of the shares above.